

## Correction: TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors

In this article (Cancer Res 2016;76:2087–93), which appeared in the April 15, 2016, issue of *Cancer Research* (1), the sequence that was used to generate the TALEN was incorrect as reported in Fig. 1. The sequence that was used is located in exon 2 and not exon 1 as reported. Hence, "CD8<sup>PD-1Ex1</sup>" and "TRL<sup>PD-1Ex1</sup>" throughout the text, figures, and supplementary data should have been "CD8<sup>PD-1Ex2</sup>" and "TRL<sup>PD-1Ex2</sup>," respectively. In addition, the correct name of the eighth author is Javier Herrero. The authors regret these errors.

The online version of the article has been corrected and no longer matches the print.

### Reference

1. Menger L, Sledzinska A, Bergerhoff K, Vargas FA, Smith J, Poirot L, et al. TALEN-mediated inactivation of PD-1 in tumor-reactive lymphocytes promotes intratumoral T-cell persistence and rejection of established tumors. *Cancer Res* 2016;76:2087–93.

Published online October 14, 2016.

doi: 10.1158/0008-5472.CAN-16-2195

©2016 American Association for Cancer Research.